Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3592]

Drug profiling and gene scissors open new avenues in immunotherapy

Drug profiling and gene scissors open new avenues in immunotherapy

New technique predicts which melanoma patients are at risk for cancer recurrence and spread

New technique predicts which melanoma patients are at risk for cancer recurrence and spread

European Commission approves daratumumab in combination with bortezomib, thalidomide and dexamethasone (VTd) for patients with newly diagnosed multiple myeloma who are transplant eligible

European Commission approves daratumumab in combination with bortezomib, thalidomide and dexamethasone (VTd) for...

Discovery of new T-cell raises prospect of ‘universal’ cancer therapy

Discovery of new T-cell raises prospect of ‘universal’ cancer therapy

B cells linked to effective cancer immunotherapy

B cells linked to effective cancer immunotherapy

Heterogeneity of liver cancer cells helps explain tumour progression in patients

Heterogeneity of liver cancer cells helps explain tumour progression in patients

B cells: New allies in sarcoma immunotherapy?

B cells: New allies in sarcoma immunotherapy?

Scientists breach brain barriers to attack tumours

Scientists breach brain barriers to attack tumours

B-cell enrichment predictive of immunotherapy response in melanoma, sarcoma and kidney cancer

B-cell enrichment predictive of immunotherapy response in melanoma, sarcoma and kidney cancer

Pembrolizumab rejected by NICE as a first-line treatment for advanced head and neck cancer

Pembrolizumab rejected by NICE as a first-line treatment for advanced head and neck cancer

More from ecancer